Selection of chronic hepatitis B therapy with high barrier to resistance

被引：166

作者：

Gish, Robert ^{[6
]}

Jia, Ji-Dong ^{[5
]}

Locarnini, Stephen ^{[4
]}

Zoulim, Fabien ^{[1
,2
,3
]}

机构：

[1] INSERM, U1052, Canc Res Ctr Lyon, F-69003 Lyon, France

[2] Univ Lyon, Inst Univ France, Lyon, France

[3] Hosp Civils Lyon, Hepatol Dept, Lyon, France

[4] Victorian Infect Dis Reference Lab, Melbourne, Vic, Australia

[5] Capital Med Univ, Beijing Friendship Hosp, Liver Res Ctr, Beijing, Peoples R China

[6] UC San Diego Hlth Syst, Ctr Hepatobiliary Dis & Abdominal Transplantat, San Diego, CA USA

来源：

LANCET INFECTIOUS DISEASES | 2012年 / 12卷 / 04期

关键词：

TENOFOVIR DISOPROXIL FUMARATE; VIRUS POLYMERASE MUTATIONS; LONG-TERM LAMIVUDINE; ADEFOVIR DIPIVOXIL THERAPY; NUCLEOSIDE-NAIVE PATIENTS; IN-VITRO CHARACTERIZATION; E-ANTIGEN SEROCONVERSION; VIRAL-DNA SYNTHESIS; HEPATOCELLULAR-CARCINOMA; ANTIRETROVIRAL THERAPY;

D O I：

10.1016/S1473-3099(11)70314-0

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Antiviral drug resistance is a crucial factor that frequently determines the success of long-term therapy for chronic hepatitis B. The development of resistance to nucleos(t)ide analogues has been associated with exacerbations in liver disease and increased risk of emergence of multidrug resistance. The selection of a potent nucleos(t)ide analogue with a high barrier to resistance as a first-line therapy, such as entecavir or tenofovir, provides the best chance of achieving long-term treatment goals and should be used wherever possible. The barrier to resistance of a given nucleos(t)ide analogue is influenced by genetic barrier, drug potency, patient adherence, pharmacological barrier, viral fitness, mechanism of action, and cross-resistance. In countries with limited health-care resources, the selection of a therapy with a high barrier to resistance is not always possible and alternative strategies for preventing resistance might be needed, although limited data are available to support these strategies.

引用

页码：341 / 353

页数：13

共 124 条

[1] Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B [J].

Ahmed, SNS ;

Tavan, D ;

Pichoud, C ;

Berby, F ;

Stuyver, L ;

Johnson, M ;

Merle, P ;

Abidi, H ;

Trépo, C ;

Zoulim, F .

HEPATOLOGY, 2000, 32 (05) :1078-1088

[2] The rtA194T Polymerase Mutation Impacts Viral Replication and Susceptibility to Tenofovir in Hepatitis B e Antigen-Positive and Hepatitis B e Antigen-Negative Hepatitis B Virus Strains [J].

Amini-Bavil-Olyaee, Samad ;

Herbers, Ulf ;

Sheldon, Julie ;

Luedde, Tom ;

Trautwein, Christian ;

Tacke, Frank .

HEPATOLOGY, 2009, 49 (04) :1158-1165

[3]

[Anonymous], 2010, TC RESMI GAZETE 0325, V27532

[4] Tenofovir Is Effective Alone or With Emtricitabine in Adefovir-Treated Patients With Chronic-Hepatitis B Virus Infection [J].

Berg, Thomas ;

Marcellin, Patrick ;

Zoulim, Fabien ;

Moller, Bernd ;

Trinh, Huy ;

Chan, Sing ;

Suarez, Emilio ;

Lavocat, Fabien ;

Snow-Lampart, Andrea ;

Frederick, David ;

Sorbel, Jeff ;

Borroto-Esoda, Katyna ;

Oldach, David ;

Rousseau, Franck .

GASTROENTEROLOGY, 2010, 139 (04) :1207-+

[5] Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation [J].

Bock, CT ;

Tillmann, HL ;

Torresi, J ;

Klempnauer, J ;

Locarnini, S ;

Manns, MP ;

Trautwein, C .

GASTROENTEROLOGY, 2002, 122 (02) :264-273

[6] Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B [J].

Buti, Maria ;

Brosa, Max ;

Casado, Miguel A. ;

Rueda, Magdalena ;

Esteban, Rafael .

JOURNAL OF HEPATOLOGY, 2009, 51 (04) :640-646

[7]

Carroúéé-Durantel S, 2008, ANTIVIR THER, V13, P381

[8] Patterns of managing chronic hepatitis B treatment-related drug resistance: a survey of physicians in Mainland China, South Korea, Taiwan, and Thailand [J].

Chainuvati, Siwaporn ;

Cheng, Jun ;

Hou, Jin Lin ;

Hsu, Chao Wei ;

Jia, Ji Dong ;

Komolmit, Piyawat ;

Kwon, So Young ;

Lee, Chang Hong ;

Li, Hong ;

Li, Ying ;

Liu, Chun Jen ;

Neo, Boon Leong ;

Peng, Cheng Yuan ;

Tanwandee, Tawesak ;

Wongcharatrawee, Suchat ;

Wu, Jaw Ching ;

Yu, Ming Lung ;

Zhang, Xin Xin .

HEPATOLOGY INTERNATIONAL, 2009, 3 (03) :453-460

[9] Long-Term Entecavir Therapy Results in the Reversal of Fibrosis/Cirrhosis and Continued Histological Improvement in Patients with Chronic Hepatitis B [J].

Chang, Ting-Tsung ;

Liaw, Yun-Fan ;

Wu, Shun-Sheng ;

Schiff, Eugene ;

Han, Kwang-Hyub ;

Lai, Ching-Lung ;

Safadi, Rifaat ;

Lee, Samuel S. ;

Halota, Waldemar ;

Goodman, Zachary ;

Chi, Yun-Chan ;

Zhang, Hui ;

Hindes, Robert ;

Iloeje, Uchenna ;

Beebe, Suzanne ;

Kreter, Bruce .

HEPATOLOGY, 2010, 52 (03) :886-893

[10] A dose-ranging study of the efficacy and tolerability of entecavir in lamivudine-refractory chronic hepatitis B patients [J].

Chang, TT ;

Gish, RG ;

Hadziyannis, SJ ;

Cianciara, J ;

Rizzetto, M ;

Schiff, ER ;

Pastore, G ;

Bacon, BR ;

Poynard, T ;

Joshi, S ;

Klesczewski, KS ;

Thiry, A ;

Rose, RE ;

Colonno, RJ ;

Hindes, RG .

GASTROENTEROLOGY, 2005, 129 (04) :1198-1209

← 1 2 3 4 5 6 7 8 9 10 →